$1.76
-0.02 (-1.12%)
Open$2.20
Previous Close$1.78
Day High$2.20
Day Low$1.73
52W High$19.91
52W Low$1.52
Volume—
Avg Volume17.8K
Market Cap3.99M
P/E Ratio—
EPS$-25.59
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,216.5% upside
Current
$1.76
$1.76
Target
$40.77
$40.77
$30.54
$40.77 avg
$54.50
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.71M | 1.62M | 1.61M |
| Net Income | -161,760 | -172,924 | -142,728 |
| Profit Margin | -9.5% | -10.7% | -8.9% |
| EBITDA | -256,082 | -275,942 | -257,647 |
| Free Cash Flow | -132,527 | -99,336 | -105,630 |
| Rev Growth | +0.4% | +1.6% | -5.5% |
| Debt/Equity | 0.26 | 0.25 | 0.24 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |